ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI KHÔNG TẾ BÀO NHỎ GIAI ĐOẠN IV BẰNG GEFITINIB BƯỚC 1 TẠI BỆNH VIỆN ĐẠI HỌC Y HÀ NỘI

Abstract

Objective: To evaluate the outcomes of first-line Gefitinib treatment in stage IV non-small cell lung cancer (NSCLC). Methods: A cross-sectional descriptive study was conducted on 51 patients with stage IV non-small cell lung cancer, harboring EGFR gene mutations, who received first-line Gefitinib treatment at Hanoi Medical University Hospital from May 2019 to May 2024. Results: The average age of patients was 65,08 ± 11,91 years, with females accounting for 58,8% and a smoking rate of 15,7%. The majority of patients had good performance status (PS) and metastasis to 1-2 organs. The ratio of EGFR exon 19 to exon 21 mutations was approximately 1:1. According to RECIST 1.1 criteria, the complete response rate was 2,0%, partial response rate was 72,5%, stable disease rate was 15,7%, and progressive disease rate was 9,8%. The median progression-free survival was 11,5 months. The most common side effects were diarrhea (25,5%) and skin rash (21,6%), all of which were Grade I-II. Conclusion: Gefitinib provides good treatment efficacy in patients with stage IV NSCLC harboring EGFR gene mutations, with most side effects being mild.